Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Polyganics Ip B V is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners, which introduces a variety of perspectives into the company's prosecution pipeline. This distribution requires the applicant to navigate the different examination styles of multiple individuals.
The prosecution activity is also spread across 2 distinct art units, suggesting that the technical subject matter of the 3 pending office actions is diverse enough to span different specialized groups. GHALI, ISIS A D is the busiest examiner for the company, currently overseeing 2 pending office actions. This means that a majority of the active workload is concentrated under a single examiner's review.
For a practitioner, the fact that GHALI, ISIS A D manages 2 pending office actions while the remaining action is handled by a second examiner creates a prioritized prosecution environment. The strategy must account for the specific preferences of GHALI, ISIS A D, who controls the majority of the pending matters. Simultaneously, the applicant must address the requirements of the 2 distinct art units involved to successfully move all 3 pending office actions toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 2 | 27.9% | +41.6% |
| NGUYEN, HA S | 1 | 58.5% | -20.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 87d overdue |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 87d overdue |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1766 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18188571 | Biomedical Polyurethanes | NGUYEN, HA S | 1766 | §102 | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 1611 | §103Other | Final Rejection | 87d overdue | Pending | Oct 14, 2022 |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 1611 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPolyganics Ip B V has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Isis A D Ghali has the most, with 2 of Polyganics Ip B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
